ReviewPediatric blood & cancer2012
Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.
Review in Pediatric blood & cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of selected musculoskeletal late effects in survivors of childhood cancer.Current pediatric reviews · 2014Pooled it
- Detection of Pathogens in the Gut Microbiome Prior to Bloodstream Infection in Children with Acute Myeloid Leukemia or Mature B-Cell Non-Hodgkin Lymphoma.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Mental Distress, Fatigue and Executive Function in Adult Survivors of Childhood Leukemia and Non-Hodgkin Lymphoma.Current oncology (Toronto, Ont.) · 2026Article
- Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study.Journal of the National Cancer Institute · 2025Article
- Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades.Journal of cancer survivorship : research and practice · 2025Observational
- Risk-Stratified Radiotherapy in Pediatric Cancer.Cancers · 2024Review
- Dose-Related Effect of Chemotherapy on Bone Mineral Density Among Pediatric Acute Lymphoblastic Leukemia Survivors.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century.Nature reviews. Clinical oncology · 2023Review
- Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Cardiovascular Risk Factor Disparities in Adult Survivors of Childhood Cancer Compared With the General Population.JACC. CardioOncology · 2023Article
- Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000-2018.EClinicalMedicine · 2023Article
- Kinetics and Role of Pancreatic Stone Protein and Midregional Proadrenomedullin as Predictors of Sepsis and Bacteremia in Children with Hematological Malignancies.Mediterranean journal of hematology and infectious diseases · 2023Article
- Article
- How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care.Medicina (Kaunas, Lithuania) · 2022Review
- "I have to do things differently now, but I make it work"-young childhood cancer survivors' experiences of self-management in everyday living.Journal of cancer survivorship : research and practice · 2022Article
- Advanced Molecular Characterisation in Relapsed and Refractory Paediatric Acute Leukaemia, the Key for Personalised Medicine.Journal of personalized medicine · 2022Article
- Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma.Blood · 2022Article
- Medical Cannabis in Pediatric Oncology: Friend or Foe?Pharmaceuticals (Basel, Switzerland) · 2022Review
- COVID-19 in Children with Cancer.Current oncology reports · 2022Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Investigations of long-term outcomes have been instrumental in designing safer and more effective contemporary therapies for pediatric hematological malignancies. Despite the significant therapeutic changes that have occurred over the last five decades, therapy modifications largely represent refinements of treatment protocols using agents and modalities that have been available for more than 30 years. This review summarizes major trends in the evolution of treatment of pediatric hematological malignancies since 1960 to support the relevance of the study of late effects of historical therapeutic approaches to the design and evaluation of contemporary treatment protocols and the follow-up of present-day survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.